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Abstract
Background: Heme oxygenase 1 (HMOX1) is the rate limiting enzyme in heme degradation and a key regulator of
inflammatory processes. In animal models the course of pancreatitis was ameliorated by up-regulation of HMOX1
expression. Additionally, carbon monoxide released during heme breakdown inhibited proliferation of pancreatic stellate
cells and might thereby prevent the development of chronic pancreatitis (CP). Transcription of HMOX1 in humans is
influenced by a GT-repeat located in the promoter. As such, HMOX1 variants might be of importance in the pathogenesis of
pancreatitis.
Methods: The GT-repeat and SNP rs2071746 were investigated with fluorescence labelled primers and by melting curve
analysis in 285 patients with acute pancreatitis, 208 patients with alcoholic CP, 207 patients with idiopathic/hereditary CP,
147 patients with alcoholic liver cirrhosis, and in 289 controls, respectively. GT-repeat analysis was extended to a total of 446
alcoholic CP patients. In addition, we performed DNA sequencing in 145 patients with alcoholic CP, 138 patients with
idiopathic/hereditary CP, 147 patients with alcoholic liver cirrhosis, and 151 controls. Exon 3 screening was extended to
additional patients and controls.
Results: S- and L-alleles of the GT-repeat, genotypes and alleles of SNP rs2071746 and non-synonymous variants detected
by sequencing were found with similar frequencies in all groups.
Conclusions: Although functional data implicate a potential influence of HMOX1 variants on the pathogenesis of
pancreatitis, we did not find any association. As rare non-synonymous HMOX1 variants were found in patients and controls,
it is rather unlikely that they will have functional consequences essential for pancreatitis development.
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Introduction
Acute pancreatitis (AP) is a potentially life threatening disease
presenting with a wide clinical spectrum that ranges from mild
discomfort to multi organ failure [1]. In the Western world, the
leading causes of AP are chole(docho)lithiasis and alcohol abuse.
Apart from the p.N34S SPINK1 variant, no other genetic
association with AP has been confirmed so far [2]. Chronic
pancreatitis (CP) is a relapsing inflammatory disease resulting in
a permanent impairment of exocrine and endocrine organ
function in many cases. In industrialised countries, chronic alcohol
abuse is the major underlying cause while nicotine abuse is an
important contributing factor [3]. Although several genetic
associations have been described for idiopathic and hereditary
CP (ICP, HP) little is known about genetic alterations that
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contribute to the pathogenesis of AP and alcoholic CP (ACP) [4–
10].
There are 2 functional heme oxygenase isoforms, the inducible
HMOX1 (also designated as HO-1; OMIM*141250) and the
constitutively expressed HMOX2 [11]. HMOX1 is a key regulator
of inflammatory processes as moderate over-expression of
HMOX1 protects cells, whereas excessive HMOX1 expression
is harmful [12]. Cellular HMOX1 content is transcriptionally
regulated and gene expression is induced by many different stimuli
such as heavy metals, inflammation, UV radiation, oxidative stress
and even by HMOX1 itself after translocalisation to the nucleus
[13]. Gene transcription in humans is modulated by the length of
a dinucleotide GT-repeat in the promoter classified in short alleles
and long alleles [14]. Previous studies demonstrated an inducible
elevation of HMOX1 activity in presence of S-alleles. For example
HMOX1 mRNA content and oxidative stress induced HMOX1
enzymatic activity are significantly higher in S-allele carriers [15].
In animal models of experimental pancreatitis, expression of
HMOX1 is up-regulated in pancreatic islet and acinar cells and
HMOX1 as well as carbon monoxide (CO) act protective [16–18].
Moreover, HMOX1 induction improves outcome after pancreas
transplantation and ameliorates microcirculatory derangements
after ischemia and reperfusion [19,20]. For the development of
CP, fibrotic remodelling of the pancreatic parenchyma is an
essential step, with a crucial role for pancreatic stellate cells (PSC)
[21]. Of note, PSC proliferation is inhibited by CO and
endogenous CO is mainly produced during the breakdown of
heme by microsomal HMOXs [22].
As such, it is reasonable to portend that different GT-repeat
alleles or other HMOX1 genetic alterations contribute to the
pathogenesis of different pancreatitis phenotypes. To investigate
the role of HMOX1 alterations in pancreatitis, we extensively
screened the GT-repeat, SNP rs2071746, and the coding sequence
in up to 446 patients with different forms of pancreatitis, 147
patients with alcoholic liver cirrhosis (ALC) and up to 413 healthy
controls.
Materials and Methods
Patients and Controls
The study was approved by the medical ethical review
committee of the University of Leipzig, Germany (Approval:
376-11-12122011). All patients gave written informed consent. AP
was diagnosed and categorised according to the Atlanta classifi-
cation [1]. We categorised patients into a group with a mild
disease course (only local complications) and a group with severe
disease course (additionally systemic complications). Diagnosis of
CP was based on two or more of the following findings: Presence
of a history of recurrent pancreatitis or recurrent abdominal pain
typical for CP, pancreatic calcifications and/or pancreatic ductal
irregularities revealed by endoscopic retrograde pancreaticogra-
phy or by magnetic resonance imaging of the pancreas and/or
pathological sonographic findings. ACP was defined in patients
who had consumed more than 80 g/d alcohol for at least two
years in men and more than 60 g/d for women [10]. HP was
diagnosed when one first-degree relative or two or more second-
degree relatives suffered from recurrent AP or CP without any
apparent precipitating factor. ICP was diagnosed in the absence of
a positive family history or known precipitating factors.
ALC was diagnosed according to results of liver biopsy (fibrosis
stage 4) or due to unequivocal clinical and laboratory findings in
men who consumed more than 80 g/d and in women who
consumed more than 60 g/d for at least 10 years. Such findings
were abnormal levels of aminotransferases, gamma glutamyl-
transpeptidase, coagulation tests, serum albumin concentration,
platelet count, complications related to liver cirrhosis like
oesophageal varices, ascites, hepatic encephalopathy and typical
liver morphology in ultra-sound or computed tomography. Other
aetiologies of liver cirrhosis were excluded by standard laboratory
tests.
In total, we analysed the GT-repeat and SNP rs2071746 in 285
patients with AP (176 male, age range 9–89 years, median 53
years; aetiology: biliary = 115, alcoholic = 68, idiopathic = 66,
post-operative = 15, post-ERCP=8, traumatic = 6, hyperlipopro-
teinaemia = 5, hyperparathyroidism= 1, drugs = 1; disease course:
mild = 205, severe = 80), 208 ACP (199 male, age range 21–79
years, median 47 years), 207 ICH/HP (100 male, age range 3–77
years, median 29 years), 147 ALC patients (111 male, age range
32–79 years, median 56 years), and in 289 controls (88 male, age
range 20–81 years, median 47 years). In addition, we investigated
the GT-Repeat in 238 ACP patients (210 male, age range 23–75
years, median 47 years).
In 145 German patients with ACP (124 male, age range 21–69
years, median 45 years), 138 patients with ICP/HP (60 male, age
range 3–75 years, median 33 years), 147 patients with ALC (see
above) and in 151 controls (50 male, age range 20–70 years,
median 45.5 years) all coding regions and transitions to non-
coding regions were analysed by uni-directional DNA sequencing.
We screened HMOX1 exon 3 in additional 301 ACP patients (267
male, age range 23–73 years, median 44 years), 110 ICP/HP
patients (41 male, age range 3–75 years, median 32.5 years), and
in 262 controls (175 male, age range 36–98 years, median 59
years) by direct DNA sequencing. The controls investigated with
the different methods were blood donors from South-West and
East Germany.
Genotyping
Analysis of the GT-repeat. Primers were synthesised
according to the published nucleotide sequences (HMOX1:
GenBank: NM_002133.2 and NG_023030.1). For classification
of the GT-repeat located in the HMOX1 promoter, we performed
PCR with fluorescent labelled primers under the conditions
described below and 35 cycles with an annealing temperature of
58uC: Forward primer 59-FAM-AGAGCCTGCAGCTTCT-
CAGA-39, reverse Primer 59-TGGAGAGGAGCAGTCA-
TATG-39. We loaded PCR products together with a size standard
onto an ABI 3100 fluorescence sequencer (Applied Biosystems) for
fragment analysis and determined the length of the amplified PCR
product as the number of GT-repeats. We classified the products
containing GT-repeats according to the literature in short repeats
(S,25) and long repeats (L$25) [23].
Melting curve analysis of rs2071746
We performed PCR in the LightCycler 480 instrument (Roche
Diagnostics) under the following conditions (volumes see below):
initial denaturation at 95uC for 5 minutes followed by 45 cycles
with denaturation at 95uC for 5 seconds, annealing at 55uC for
20 seconds, primer extension at 72uC for 20 seconds. Primers had
the following oligonucleotide sequences: Forward primer 59-
CAAGCAGTCAGCAGAGGATTC-39, reverse primer 59-
GCAGGCTCTGGGTGTGATT-39. We performed melting
curve analysis using a pair of fluorescent resonance energy transfer
(FRET) probes. FRET probes were designed complementary to
the mutated sequence. Probes were devised and synthesised by
TIB Molbiol (Berlin, Germany): Anchor probe 59-LC640-
GCGCTGCCTCCCAGCTTTCTGGAA-39, sensor probe 59-
CACCAGGCTATTGCTCTGAGC-FL-39. Analytical melting
HMOX1 Variants in Pancreatitis
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37981
included the following steps: 95uC for 5 seconds, 40uC for
20 seconds and an increase to 80uC at a 0.29uC/s ramp rate.
Polymerase Chain Reaction and DNA sequencing
We extracted genomic DNA from peripheral blood leukocytes
and performed PCR using 0.75 U AmpliTaq Gold polymerase
(Applied Biosystems), 400 mM dNTPs, 1.5 mM MgCl2 and
0.1 mM of each primer in a total volume of 25 ml. Cycle
conditions were as follows: an initial denaturation for 12 minutes
at 95uC followed by 48 cycles of 20 seconds denaturation at 95uC,
40 seconds annealing at specific temperatures, 90 seconds primer
extension at 72uC and a final extension for 2 minutes at 72uC in
an automated thermal cycler. Oligonucleotide sequences and
annealing temperatures of the primers are listed in Table S1.
We digested PCR products with shrimp alkaline phosphatase
(USB) and exonuclease I (GE Healthcare) and performed cycle
sequencing using BigDye terminator mix (Applied Biosystems). We
purified reaction products with ethanol precipitation and loaded
them onto an ABI 3100 fluorescence sequencer (Applied
Biosystems). Mutations are described according to the nomencla-
ture recommended by the Human Genome Variation Society
(http://www.hgvs.org/mutnomen) following a common consensus
with mutation numbering which defines the A of the ATG start
codon as nucleotide +1.
Statistics
We tested the significance of the differences between variant
frequencies in affected individuals and controls by two-tailed
Fisher’s Exact test. P-values were calculated using GraphPad
Prism (v 4.03). For SNPs we utilised a dominant model, defined as
AA vs. AG+GG (e.g. for c.736+226A.G, rs2269533), for
calculations and considered p-values ,0.05 to be of statistical
significance. In addition, calculations were performed following
a recessive model (AA+AG vs. GG) and for allele frequencies. We
used the first allele in the variant description as the major allele
(example above for c.736+226A.G, rs2269533). The p-values are
shown without correcting for multiple testing.
Results
Fragment length analyses of the promoter GT-repeat
Our analysis of the GT-repeat revealed repeats ranging from 12
to 40 GTs. In all groups we detected alleles with 23 (AP 19.7%,
ACP 24.2%, ICP/HP 21.1%, ALC 22.8%, controls 19.7%) and
30 repeats (AP 42.5%, ACP 45.6%, ICP/HP 48.1%, ALC 41.5%,
controls 43.8%) with highest frequencies in accordance with
previous reports [23]. In AP patients, frequencies of S- and L-
alleles were similar to frequencies obtained in controls (S-allele:
173/578, 29.9%) even after categorization in mild (S-allele: 134/
410, 32.7%; p-value 0.4) and severe disease course (S-allele: 55/
160, 34.4%; p-value 0.3) (mild vs. severe: p-value 0.7). In our first
screen of 208 ACP patients, we found S-alleles (145/416, 34.9%)
more common in patients than in controls (p-value 0.1). Although
this finding was not statistically significant, we extended our
analysis and after screening of additional 238 ACP patients we
strengthened the preliminary results and ruled out an association
(p-value 0.4). In all other groups distribution of alleles was similar
in patients and controls (Table 1).
SNP analyses
There was no difference in the genotype and allele frequency
distribution of SNP rs2071746 (g.4613A.T) in AP, ACP, ICP/
HP, and ALC patients compared to controls (Table 2). Even after
categorization into mild (A-allele: 229/410, 55.9%; Genotype: AA
60/205, 29.3%; AT 109/205, 53.2%) and severe (A-allele: 84/
160, 52.5%; Genotype: AA 25/80, 31.3%; AT 34/80, 42.5%)
disease course no difference was obtained in the AP group
compared to controls (all p-values not significant).
Table 1. GT-repeat analysis in acute pancreatitis (AP),
alcoholic chronic pancreatitis (ACP), idiopathic/hereditary
chronic pancreatitis (ICP/HP), and alcoholic liver cirrhosis
(ALC) patients and in controls.
Alleles Patients Controls p-Value
AP
S 189/570 (33.2%) 173/578 (29.9%) n.s
L 381/570 (66.8%) 405/578 (70.1%)
ACP
S 286/892 (32.1%) 173/578 (29.9%) n.s
L 606/892 (67.9% 405/578 (70.1%)
ICP/HP
S 125/412 (30.3%) 173/578 (29.9%) n.s
L 287/412 (69.7%) 405/578 (70.1%)
ALC
S 91/294 (31%) 173/578 (29.9%) n.s
L 203/294 (69%) 405/578 (70.1%)
S-alleles were defined as ,25 GT-repeats, whereas L-alleles represented $25
GT-repeats. Abbreviations: S = S-allele, L = L-alleles, n.s. = not significant.
doi:10.1371/journal.pone.0037981.t001
Table 2. Genotype data of SNP rs2071746 in acute
pancreatitis (AP), alcoholic chronic pancreatitis (ACP),
idiopathic/hereditary chronic pancreatitis (ICP/HP), and
alcoholic liver cirrhosis (ALC) patients and in controls.
Variant Genotype Patients Controls p-Value
g.4613A.T
rs2071746
AP
AA 85/285 (29.8%) 96/289 (33.2%) n.s.
AT 143/285 (50.2%) 142/289 (49.1%)
TT 57/285 (20%) 51/289 (17.6%)
ACP
AA 62/208 (29.8%) 96/289 (33.2%) n.s.
AT 107/208 (51.4%) 142/289 (49.1%)
TT 39/208 (18.8%) 51/289 (17.6%)
ICP/HP
AA 73/207 (35.3%) 96/289 (33.2%) n.s.
AT 104/207 (50.2%) 142/289 (49.1%)
TT 30/207 (14.5%) 51/289 (17.6%)
ALC
AA 51/147 (34.7%) 96/289 (33.2%) n.s.
AT 68/147 (46.3%) 142/289 (49.1%)
TT 28/147 (19%) 51/289 (17.6%)
Abbreviations: n.s. = not significant.
doi:10.1371/journal.pone.0037981.t002
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DNA sequencing
By DNA sequencing of the complete coding region, we found
five common HMOX1 variants (c.144+4T.C, rs17885925;
c.145219C.T, rs17879606; c.736+52delTinsTGGCTGTCT-
GACT, rs17882597; c.736+226A.G, rs2269533;
c.736+270T.C, rs2269534) in patients and controls (Table S2).
Apart from SNP rs2269534 in ACP patients, frequencies of all
SNPs were similar in patients and controls and the distribution
showed no statistical significant difference when allele frequencies
and genotypes were compared. In ACP patients allele frequencies
of SNP rs2269534 differed significantly between patients (T-allele:
166/260, 63.9%) and controls (195/270, 72.2%) (p-value 0.04,
OR 1.5, 95% CI 1.02–2.13), but the association did not withstand
Bonferroni correction (pc-value 0.2).
We identified non-synonymous variants and variants with
a minor allele frequency ,5% in 25/145 (17.2%) ACP patients
and in 27/151 (17.9%) controls (Table 3). Non-synonymous
variant c.19G.C (p.D7H, rs2071747) was detected in similar
frequencies in ACP patients (14/145, 9.7%) and controls (15/151,
9.9%). We found variants c.379G.T (p.E127X) and c.577C.T
(p.P193S) in patients only (1/145, 0.7%; 2/145, 1.4%), whereas
we detected variant c.101T.C (p.M34T) in one control only (1/
151, 0.7%). None of the variants showed a statistical significant
difference of their frequencies in patients and controls.
In the cohort of ICP/HP patients, only one patient (1/138,
0.7%) carried a non-synonymous variant (c.407G.A, p.R136H)
apart from c.19G.C (11/138, 7.2%). In patients with ALC, no
patient carried a non-synonymous variant other than c.19G.C
(11/147, 7.5%). Overall, we observed no significant difference in
the distribution of variants in both patient groups compared to
controls.
To elucidate the role of non-synonymous exon 3 variants
(c.379G.T, c.407G.A, and c. 577C.T), we extended our
analyses (Table 4). Subsequently, we found variant c.379G.T in
1/446 (0.2%) ACP patients, but not in ICP/HP patients or
controls, variant c.577C.T in 2/446 (0.4%) ACP patients and in
2/248 (0.8%) ICP/HP patients compared to 2/413 (0.5%)
controls, and variant c.407G.A in 1/248 (0.4%) ICP/HP
patients, but not in 413 controls. In addition, we identified
a hitherto undescribed variant c.473C.T (p.P158L) in one
control subject. In summary, none of the variants alone or
combined showed a significant difference in their distribution
between patients and controls (Table 4).
Discussion
The current study investigates the influence of genetic HMOX1
alterations in different types of pancreatitis since there is evidence
that HMOX1 induction might influence the development and the
course of AP and the pathogenesis of CP by inhibition of PSC
proliferation. The finding of a genetic association with different
pancreatitis forms would support efforts to study HMOX1
induction by drugs or by application of hemin in a clinical setting.
However, we did not find any association between the HMOX1
GT-repeat and any of the investigated pancreatitis phenotypes. We
observed a trend towards an enrichment of S-alleles in AP and
ACP, but this finding is counterintuitive as the S-allele has been
associated with more HMOX1 activity and thereby probably
protects against the development of pancreatitis [15].
Table 3. Rare variants identified by sequencing of HMOX1 in alcoholic chronic pancreatitis (ACP), idiopathic/hereditary chronic
pancreatitis (ICP/HP), and alcoholic liver cirrhosis (ALC) patients and controls and their location within HMOX1.
Variant Location ACP ICP/HCP ALC Controls p-Value
c.2120A.T 59-UTR 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.288T.C 59-UTR 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.213C.T (rs9282701) 59-UTR 1/145 (0.7%) 0/138 1/147 (0.7%) 1/151 (0.7%) n.s.
c.19G.C (rs2071747), p.D7H Exon 1 14/145 (9.7%) 11/138 (7.2%) 11/147 (7.5%) 15/151 (9.9%) n.s.
c.101T.C, p.M34T Exon 1 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.23+28_29delCGGGACG Intron 1 1/145 (0.7%) 1/138 (0.7%) 1/147 (0.7%) 0/151 n.s.
c.23+91G.A Intron 1 1/145 (0.7%) 3/138 (2.2%) 0/147 2/151 (1.3%) n.s.
c.23+241C.T Intron 1 0/145 2/138 (1.5%) 2/147 (1.4%) 1/151 (0.7%) n.s.
c.144+206delTGT Intron 2 0/145 0/138 1/147 (0.7%) 1/151 (0.7%) n.s.
c.144+246C.T Intron 2 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.144+272C.T Intron 2 0/145 0/138 1/147 (0.7%) 0/151 n.s.
c.234C.T, (p.( = )) Exon 3 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.330C.T, (p.( = )) Exon 3 1/145 (0.7%) 0/138 0/147 1/151 (0.7%) n.s.
c.379G.T, p.E127X Exon 3 1/145 (0.7%) 0/138 0/147 0/151 n.s.
c.407G.A, p.R136H Exon 3 0/145 1/138 (0.7%) 0/147 0/151 n.s.
c.577C.T, p.P193S Exon 3 2/145 (1.4%) 0/138 0/147 0/151 n.s.
c.621C.T, (p.( = )) Exon 3 1/145 (0.7%) 0/138 0/147 0/151 n.s.
c.736+322G.A Intron 4 0/145 1/138 (0.7%) 0/147 0/151 n.s.
c.736+331G.A Intron 4 0/145 0/138 0/147 1/151 (0.7%) n.s.
c.*71C.G 39-UTR 0/145 2/138 (1.5%) 0/147 0/151 n.s.
c.*149A.G 39-UTR 3/145 (2.1%) 1/138 (0.7%) 1/147 (0.7%) 0/151 n.s.
Abbreviations: n.s. = not significant.
doi:10.1371/journal.pone.0037981.t003
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In earlier studies, the GT-repeat length in the HMOX1 promoter
has been associated with several human diseases. To cite coronary
artery disease patients as an example, patients with S-alleles had
a higher risk at restenosis after coronary stenting [24]. Apart from
the GT-repeat, previous studies implied a potential influence of the
AA-genotype of SNP rs2071746 (g.4613A.T) located in the 59-
region of HMOX1 in hypertension and coronary artery disease
[25,26]. On the functional level, the A allele and longer (.30 GT)
repeats have been shown to elicit a higher basal promoter activity
[25]. We investigated this variant in our patients and controls and
found no association with any type of pancreatitis. As such, our
data probably rule out that HMOX1 promoter variants modulate
the risk for pancreatitis of any aetiology. In addition, smoking
represents a risk factor for pancreatitis and HMOX1 alterations
seem to influence the susceptibility to smoking related disorders
[27]. However, we were not able to demonstrate differences of
HMOX1 alterations in patients that were smokers compared to
non-smokers (data not shown). Noteworthy, the number of
individuals in that smoking habits were available was rather small
(n = 65) and as such these results have to be interpreted with
caution.
In ICP/HP several genetic associations have been described
with rare variants over the last years [4–10]. To rule out an
association of rare HMOX1 variants with diverse CP forms we
extensively analysed the HMOX1 coding regions by DNA
sequencing. In summary, none of the detected non-synonymous,
synonymous or non-coding variants showed an association with
ICP/HP or ACP even after extension of our screening cohorts.
Noteworthy, in most of the disease entities associated with GT-
repeat variants the coding region has not been investigated
comprehensively. Therefore, the role of HMOX1 coding variants
in other disease forms unlike pancreatitis is not thoroughly
clarified.
Study limitations
Our study has some limitations. The control group used for
comparison are blood donors. As such this introduces potential
bias because ALC, ACP or other pancreatitis forms might be
present among blood donors. We surmise that the contribution of
such a bias is rather small. In Germany all blood donors are
routinely screened for elevated liver enzymes and persons with
chronic alcohol abuse are not suitable to donate blood. Lastly, the
number of ALC patients is relatively small which limits the power
of this part of our study.
In conclusion, our results implicate that HMOX1 variants are
unimportant in different forms of pancreatitis and ALC. Notably,
HMOX1 is induced by different stimuli and the impact of genetic
variants might be minor for a substantial decrease or increase of
HMOX1 expression in AP, CP or ALC. Although data obtained
in experimentally induced AP picture HMOX1 as a potential
target in pancreatitis, we cannot further support this view on the
basis of our genetic case control study. Nevertheless, pharmaco-
logic approaches influencing HMOX1 activity might have
a benefical effect even in humans.
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Abbreviations: PCR=polymerase chain reaction, SEQ= sequen-
cing, F= forward, R= reverse.
(DOCX)
Table S2 Frequencies of common intronic variants in
ACP, ICP/HP, and ALC patients. P-values are given for
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